Initially established for the use in chronic myelogenous leukemia (CML) by targeting the BCR-ABL1 fusion protein, the outstanding therapeutic success made tyrosine kinase inhibitors a prominent example of the concept of targeted therapy. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.